Gossamer Bio’s (GOSS) Buy Rating Reiterated at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock.

Separately, Wedbush reissued an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Down 4.1 %

Shares of Gossamer Bio stock opened at $1.39 on Tuesday. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55. The business has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $0.97. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a market cap of $314.98 million, a PE ratio of -4.34 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million. Research analysts predict that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Trading of Gossamer Bio

A number of large investors have recently bought and sold shares of GOSS. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio in the third quarter valued at approximately $67,000. US Bancorp DE bought a new stake in Gossamer Bio in the 3rd quarter valued at $39,000. The Manufacturers Life Insurance Company boosted its stake in Gossamer Bio by 24.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after purchasing an additional 74,920 shares during the period. Monaco Asset Management SAM increased its holdings in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after purchasing an additional 442,895 shares during the period. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.